Author Insights: Publishing with Clinical Nuclear Medicine Open

About the author 

The insightful research comes from Dr. Joshua Eichhorn, an assistant professor in the Department of Radiology and the division chief of Nuclear Medicine at the University of Arkansas for Medical Sciences. With research interests that include multiple myeloma, Dr. Eichhorn is dedicated to advancing the field of nuclear medicine.

Dr. Eichhorn’s research

99mTc-Sestamibi SPECT/CT Evaluation of Renal Oncocytomas

Dr. Eichhorn’s article, "99mTc-Sestamibi SPECT/CT Evaluation of Renal Oncocytomas," presents a non-invasive method for differentiating between two common types of renal tumors: benign renal oncocytomas and malignant renal cell carcinomas. This is crucial because some patients are not suitable candidates for traditional diagnostic methods like biopsy.

The article details how 99mTc-sestamibi SPECT/CT imaging can be used to identify renal oncocytomas with high accuracy. The technique leverages the high mitochondrial content found in renal oncocytomas, which causes them to absorb the sestamibi tracer. Previous studies have shown this method to be approximately 87 percent sensitive and 95 percent specific for identifying these benign tumors.

By presenting two detailed case reports, the article provides practical evidence of the scan's utility. It serves as a valuable resource for clinicians seeking alternative, non-invasive diagnostic tools, especially when managing complex cases involving patients with rare tumors where large-scale studies are difficult to conduct.

Why publish with Clinical Nuclear Medicine Open?

Choosing the right journal is as important as the research itself. Dr. Eichhorn shared his positive experience publishing with Clinical Nuclear Medicine Open, highlighting several factors that made it the ideal platform for his work.

A home for valuable case reports

Many prominent radiology journals no longer accept case reports or small case series. Dr. Eichhorn noted the importance of publishing these findings, especially for rare tumors where large studies are challenging. He explained, "Clinical Nuclear Medicine Open provided a platform to publish a case report or small case series with good reviewer feedback as well as a very reasonable publishing cost for an open access publication." This makes the journal an excellent platform for researchers to publish interesting cases and contribute to the medical community.

A streamlined and supportive process

Dr. Eichhorn described his overall experience as "very favorable." He was particularly impressed with the journal's efficiency and user-friendly systems. Key benefits included:

• Quick turnaround: He received concise and helpful reviewer comments just a week after submission. After making minor corrections, the manuscript was accepted very quickly.

• User-friendly platform: The editing platform was intuitive, making it simple to respond to editor comments, address formatting, and complete necessary declarations. Dr. Eichhorn mentioned that these tasks could be completed "in just a few minutes."

• No hidden costs: Unlike many other journals, Clinical Nuclear Medicine Open does not charge additional fees for color images in online publications, which helps keep publishing costs reasonable.

• Seamless manuscript transfer: Dr. Eichhorn initially submitted his article to Clinical Nuclear Medicine. The reviewers felt it was a better fit for Clinical Nuclear Medicine Open and suggested a transfer. He used the Lippincott® Transfer Desk, which made the process effortless. "I received an email with this suggestion, and this was a simple click of a link. Lippincott provided very nice step-by-step instructions, and the whole submission process was very easy to follow," he recalled.

Dr. Eichhorn’s experience highlights that Clinical Nuclear Medicine Open provides a supportive and accessible platform for researchers to share meaningful clinical findings that can directly improve patient care. With its efficient system and dedicated support, the journal promotes the dissemination of research that advances healthcare outcomes.